Background-Significant prosthetic paravalvular leakage (PVL) could have serious clinical consequences and impairs survival. Reoperation is associated with a high mortality rate, and transcatheter closure is a new treatment modality for high-risk patients. The goal of this study was to determine safety and midterm clinical efficacy of transcatheter PVL closure using an open transapical approach. Methods and Results-All consecutive patients who underwent transcatheter PVL closure in our center were prospectively enrolled. Pre-and postprocedural quality of life and 6-minute walk test were ascertained. All outcomes were defined according to the Valve Academic Research Consortium-2 consensus document. In total, 37 consecutive patients (mean age 67±12 years, 65% male, logistic European System for Cardiac Operative Risk Evaluation 27±17%, Society of Thoracic Surgeons score 7±4%) with severe symptomatic PVL in mitral (81%) or aortic (19%) position underwent transcatheter PVL closure. Procedure success was 86%. Early safety at 30 days (ie, event-free survival) was 84%. The 1-year survival rate was 66%. New York Heart Association functional class and quality of life significantly improved. Clinical efficacy (ie, survival free of stroke, rehospitalization, New York Heart Association 3/4, and device-related dysfunction) was 49% at 3 months and 31% at 1 year. Moderate to severe residual PVL was associated with all-cause mortality (hazard ratio, 3.9; 95% confidence interval, 1.2-12.1; P=0.03). Conclusions-The open transapical approach to PVL closure in high-risk patients has a high procedural success rate with an acceptable risk of adverse outcomes. This is the first study to prove an increased functional capacity and quality of life after transapical PVL closure. Residual PVL is associated with 1-year mortality. (Circ Cardiovasc Interv. 2014;7:611-620.) Key Words: heart failure ◼ heart valve diseases ◼ heart valve prosthesis ◼ mitral valve insufficiency ◼ quality of life ◼ septal occluder device ◼ surgical procedures, minimally invasive
P rosthetic paravalvular leakage (PVL) is a well-known complication of surgical valve implantation. 1 PVL is defined as a periprosthetic regurgitation through a defect between the annulus of the native valve and the sewing ring. The occurrence of PVL has been recognized for quite some time but gained more attention since the introduction of transcatheter aortic valve implantation and its concurrent relatively high rate of PVL.
Significant PVL could have major clinical consequences and impacts long-term survival. 2, 3 Until the late 1990s, reoperation was the only solution despite a mortality rate of ≈5% to 14%. [4] [5] [6] With the use of transcatheter interventions and the introduction of vascular plugs, efforts have been made to seal PVLs percutaneously mainly by transfemoral approach, with variable success. By contrast, we opt for a standard transapical approach using a minithoracotomy because we think that this enables a simpler crossing of the PVL and a more stable catheter position to deliver the plugs.
Conclusive literature is not available on transcatheter PVL closure via the open transapical approach. Accordingly, we examined the procedural and midterm clinical outcomes of transapical transcatheter PVL closure in consecutive patients.
Methods

Patient Population
All consecutive patients with a significant PVL who underwent a transcatheter PVL closure by means of an open transapical approach in the period between October 2009 and April 2013 at the St Antonius Hospital were enrolled in this study. PVL was graded semiquantitatively using Doppler transoesophageal echocardiography and color-flow imaging by echocardiographers experienced in the intraoperative assessment of mitral and aortic valve repair and replacement. 7, 8 Circumference of PVL was measured on 3-dimensional color-flow imaging. 7 The location of PVL was determined by a modified clock-face system in the surgical view, as previously described. 9 PVL was classified according to the Valve Academic Research Consortium (VARC)-2 Consensus 10 as: 0 (none), I (mild), II (moderate), or III (severe).
Patients were considered eligible for transcatheter closure if the following criteria were met: (i) the patient had a PVL grade II or greater, (ii) the patient had severe symptoms of congestive heart failure (New York Heart Association [NYHA] functional class>2) and hemolytic anemia, as differentiated from symptoms related to comorbid conditions, (iii) a heart team, consisting of ≥1 experienced cardiothoracic surgeon, interventional cardiologist, and imaging specialist, deemed the perioperative risk of major morbidity or mortality exceeding the potential benefits of reoperation, generally due to the presence of comorbid conditions.
Quality of life (QoL) was scored using Minnesota Living with Heart Failure Questionnaire. Functional capacity was estimated according to NYHA functional class and a 6-minute walk test . Procedure risk was estimated with the logistic European System for Cardiac Operative Risk Evaluation and the Society of Thoracic Surgeons score.
All patients were physically evaluated by ≥1 cardiac surgeon and informed about the considerations and risks prior to intervention. The present investigation was approved by the local institution ethical committee (registration number: R&D/Z-13.33). The first 7 patients have also been published previously by Swaans et al. 11 
Procedure
In brief, we exposed the left ventricular apex by a small anterolateral left thoracotomy at the fifth intercostal space using single-lumen tube ventilation only. After removal of some pericardial fat, we opened the pericardium longitudinally and sutured it to the thoracic wall to optimize exposure. We put 2 purse-string sutures (Prolene 3-0) with felt pledgets just lateral to the left anterior descending coronary artery near the apex, where epicardial fat is usually minimally present. Following heparin, aimed at an activated clotting time of ≈250 seconds, we punctured the apex and introduced a 25-cm 9F sheath under fluoroscopic guidance. Next, we passed the PVL using an angled Terumo guidewire and an angiographic Amplatz I diagnostic catheter under single-plane fluoroscopy and real-time 3D-transoesophageal echocardiography guidance. After passage, we carefully forwarded the catheter and exchanged the guidewire by a stiff wire. We reintroduced the dilator and gently forwarded the 9F sheath through the PVL. Depending on the size and morphology of the defect and the angle and distance to prosthetic valve leaflets, the most appropriate occluder device was selected and advanced through the defect. We mainly used Amplatzer vascular plugs (AVP and AVPIII), but also the Amplatzer ventricular septal defect occluder, and Occlutech Figulla Flex atrial septal defect occluder ( Figure 1 ). After deployment of the first half of the plug at atrial or aortic level, we used real-time 3D-transoesophageal echocardiography to orient the oval plug along the annulus. Next, we retracted the sheath into the left ventricle to allow the plug to unfold completely and close off the PVL. If not satisfied by its position, we gently pulled on the wire while forwarding the sheath, folding in the plug again to reposition it. Gentle pulling and pushing on the fixation wire may confirm a stable position. After excluding leaflet impingement and acquiring a satisfactory PVL closure effect, we released the plug. Multiple plugs may be positioned using this approach. As an alternative, multiple guidewires may be positioned through the PVL(s) to allow plug deployment in series, without the difficulty to pass a residual PVL again and risking inadvertent migration as well. However, when using one catheter, the previous plug has to be released before the PVL can be crossed again to implant an additional plug, risking embolization.
Last, we retracted the sheath and secured the 2 s. We approximated the pectoral fascia and subcutaneous tissue and closed the skin by absorbable Vicryl sutures, leaving a left pleural drain until the next day. All patients were transferred to the Intensive Care Unit for ≥1 day.
The procedure time was defined as the time frame from incision to skin closure. Procedure-related death was defined as all-cause mortality ≤30 days or during index hospitalization if >30 days. Procedure success was defined as device success defined in VARC-2 10 : freedom of procedure mortality, correct positioning of the closure device, and the intended performance of the closure device (no moderate or severe PVL).
Adverse Events
All procedure and midterm complications were reported. Outcomes were defined according to the VARC-2 Consensus. 10 Bleeding complications were classified according to the consensus report from the Bleeding Academic Research Consortium. 12 Acute kidney injury was classified using the Acute Kidney Injury Network classification system. 13 Clinically significant hemolytic anemia was defined as anemia (hemoglobin<7.0 mmol/L in women and <7.8 mmol/L in men) with laboratory evidence of intravascular hemolysis. Early safety was defined as freedom of all-cause mortality, stroke, life-threatening bleeding, acute kidney injury (Acute Kidney Injury Network class II or
WHAT IS KNOWN
• Paravalvular leakage after surgical prosthetic valve replacement can cause severe symptoms of congestive heart failure and hemolytic anemia. • In high-risk or inoperable patients, transcatheter closure of a paravalvular leaks has been reported as an alternative to surgery that is successful in ≈80% of patients.
WHAT THE STUDY ADDS
• Transcatheter paravalvular leak closure using an open transapical approach was associated with improvements in functionality, quality of life, hemolytic anemia, and congestive heart failure, with a similar success rate as other methods of closure. • Moderate to severe residual paravalvular leakage was associated with a higher rate of 1-year mortality than lower grades of residual leakage. III including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication as defined by VARC-2, 10 and device-related valvular dysfunction requiring repeat procedure. Early safety was measured at 30 days.
Efficacy
Clinical efficacy was defined as freedom of all-cause mortality, stroke, rehospitalization for PVL-related symptoms (anemia or congestive heart failure), NYHA functional class 3 or 4, and closure device-related dysfunction (moderate or severe PVL). Clinical efficacy was measured at 3 months and 1 year.
Follow-Up
Before discharge, a transthoracic echocardiography was performed within 7 days after PVL closure. Ambulatory visit and laboratory tests were scheduled at 3, 6, and 12 months and yearly thereafter. At each visit, the patient was asked to fill in the Minnesota Living with Heart Failure Questionnaire and perform a 6-MWT. Standard transthoracic echocardiography was performed at 3 and 12 months and yearly thereafter. Patients' vital status was ascertained from the national death registry. Cause of death was determined by contacting the referring physician or general practitioner.
Data Analysis
Data are presented as mean±SD or as median with the 25th and 75th percentiles as appropriate. Categorical variables are shown as frequencies and percentages. For continuous variables, a Student t test or Mann-Whitney U test was used for comparison between 2 groups. For prepost comparison we used paired-sample t test or the Wilcoxon signed-rank test as appropriate. Proportions were compared using Fisher exact test. Correlations were examined by calculating Spearman rank correlation coefficient. Survival estimates were calculated for study end points using the Kaplan-Meier method and compared by means of the log-rank test. To examine the role of PVL type, patients were grouped according to aortic and mitral PVL. To examine the role of residual PVL on outcome, patients were grouped according to none or mild and moderate or severe PVL before discharge. To examine the impact of the distance covered during the preprocedure 6-MWT on the outcome, patients were grouped according to a distance of <300 m or ≥300 m. 14 Hazard ratio with 95% confidence interval (CI) was calculated using Cox proportional hazards regression, and odds ratio with 95% CI was calculated using binominal logistic regression. Statistical significance was inferred at P<0.05.
Results
Patients
The study comprised 37 consecutive patients (mean age 67±12 years, 65% male, logistic European System for Cardiac Operative Risk Evaluation 27±17%, Society of Thoracic Surgeons score 7±4%). All patients had congestive cardiac failure and had an NYHA functional class>2. Hemolytic anemia was present in 28 patients (76%) and significant comorbidity was common. Baseline characteristics are listed in Table 1 .
Paravalvular Leakage
The treated defects most commonly involved mechanical (76%) and mitral prostheses (81%). Most patients had a severe PVL (76%). Most mitral PVLs were located posterolaterally. Most aortic PVLs were located between the native noncoronary and right coronary cusps. Mean PVL circumference was higher for mitral versus aortic lesions (19±9% versus 10±5%, P=0.02). PVL characteristics are listed in Table 1 . PVL locations are visualized in Figure 2 . 
Procedure
Procedure success (ie, procedural survival free of incorrect closure device positioning and residual moderate or severe PVL) was present in 32 of 37 procedures (86%; 95% CI, 74-92%). The mean procedure time was 89±31 minutes. The mean procedure time was longer for patients with an aortic (126±35 minutes) versus mitral PVL (79±23 minutes; P=0.07). The grade of PVL or its circumference did not correlate with the procedure success.
No patients had device embolization, but device malpositioning occurred in 2 cases. In the first case, device migration occurred without distal embolization of 1 of 3 implanted AVPIII plugs involving a mechanical mitral prosthesis. This patient died at day 1 due to a significant residual PVL with severe deteriorated congestive heart failure. In the second case, impingement of a mechanic mitral prosthesis occurred with a severe residual PVL and valvular regurgitation due to interference with a muscular ventricular septal defect occluder and the inability of the lateral leaflet to close ( Figure 3 ; Movie I in the Data Supplement). This patient underwent a successful redo mitral valve replacement at day 5. One patient required a rethoracotomy at day 0 because of a hematothorax and developed severe fixed suprasystemic pulmonary hypertension and died at day 4 due to refractory cardiogenic shock. Despite device implantation, 2 patients had a persistent severe PVL for which reoperation was performed. No transcatheter reintervention was performed. Procedure outcomes are listed in Table 2 .
Adverse Events
The safety end point (ie, survival free of stroke, life-threatening bleeding, severe acute kidney injury, coronary artery obstruction requiring intervention, major vascular complication, and device-related valvular dysfunction requiring repeat procedure) was met in 31 of 37 patients (84%; 95% CI, 69-92%). Four patients developed a hematothorax for which a left-sided rethoracotomy was required. Three out of four hematothoraces occurred within the first 10 patients. In 3 cases, no active bleeding site could be found. In 1 case, an active apical bleeding was identified and sutured. The overall rate of bleeding complications was 19% at 30 days. Major bleedings consisted of melena (n=2) and minor bleedings consisted of hematuria (n=2). All complications are listed in Table 3 .
Efficacy
The efficacy end point (ie, survival free of stroke, rehospitalization, NYHA 3/4, and moderate or severe PVL) was met in 19 of 37 patients (51%) at 3 months and in 9 of 29 patients (31%) at 1 year. At 3 months, 3 patients (8%) died, 4 patients (11%) were rehospitalized due to decompensated heart failure, 12 patients (32%) had a NYHA functional class >2, and 2 patients (5%) developed a new severe PVL. At 1 year, 10 of 29 patients (34%) had died, 9 patients (31%) were rehospitalized due to decompensated heart failure (n=7) or anemia requiring blood transfusion (n=2), 15 patients (52%) had a NYHA functional class >2, and 3 patients (10%) had a moderate to severe PVL. No anatomic or procedural parameters directly affected the clinical efficacy. Hemolytic anemia requiring blood transfusion persisted in 3 of 18 patients (17%) although hemolytic parameters decreased and hemoglobin increased. The logistic levels of N-terminal prohormone of brain natriuretic peptide decreased at 6 months (P<0.01). The median NYHA functional class improved from 3 (3-4) to 2 (2-3) at 6 months (P<0.01), and the distance covered by 6-MWT tended to improve with ≈50 m at 6 months (P=0.150). The QoL improved (P=0.01) and was correlated with the 6-MWT (Spearman −0.829, P=0.02) at follow-up. The median PVL grade reduced significantly at 1-year follow-up. Any residual PVL at discharge was present in 18 patients (49%). Functional, laboratory, and echocardiographic parameters are listed in Table 4 .
Follow-Up
Median follow-up was 9.5 (4.1-19.9) months. One-year follow-up was completed for 29 patients (78%). At 1-year follow-up, 10 patients (34%) had died. Cardiovascular mortality was 31% (n=9) due to congestive heart failure in 8 patients and of unknown cause in 1 patient. Noncardiovascular death occurred in 1 patient, who died of a pneumosepsis after 7.5 months.
At 1-year follow-up, 100% of patients with an aortic lesion were alive versus 57% of patients with a mitral lesion. Moderate to severe PVL before discharge was associated with all-cause mortality (hazard ratio, 3.9; 95% CI, 1.2-12.1; P=0.03) as shown in Figure 4A . Survival free of reoperation was 62% (n=18) at 1 year ( Figure 4B ). Furthermore, 1-year survival was higher in patients with ≥300 m than <300 m walking distance at baseline (100% versus 60%, P=0.03; Figure 4C ). No sex-based differences were present.
Discussion
The principle findings of this study are that (i) transapical transcatheter PVL is associated with a similarly low incidence of adverse procedural events compared with other closure methods in patients with high surgical risk, (ii) transapical transcatheter PVL closure has a moderate efficacy but improves symptoms and QoL, and (iii) residual moderate to severe PVL is associated with higher 1-year mortality.
Transapical Access
Transcatheter PVL closure can be performed using either a retrograde or anterograde approach. We preferentially perform Values are n (%). One-year follow-up is completed for 29 patients (76%). AKIN indicates Acute Kidney Injury Network.
*Bleeding was classified according to the consensus report from the Bleeding Academic Research Consortium. 12 †Acute kidney injury was classified using the Acute Kidney Injury Network classification system. 13 ‡Total number of patients at 1-year follow-up is 20 for mitral valve and 7 for aortic valve. §Composite end points are defined according to the Valve Academic Research Consortium-2 Consensus. 10 ║Procedure success is defined as procedural survival free of incorrect closure device positioning and residual moderate or severe paravalvular leakage (PVL).
¶Early safety is defined as survival free of stroke, life-threatening bleeding, severe acute kidney injury, coronary artery obstruction requiring intervention, major vascular complication, and device-related valvular dysfunction requiring repeat procedure.
#Clinical efficacy is defined as survival free of stroke, rehospitalization, New York Heart Association functional class 3/4, and moderate or severe PVL.
transcatheter PVL closure using an open transapical access, which provides a retrograde mitral and anterograde aortic approach. The advantages are that (i) both valves are easily accessible, (ii) a mechanical heart valve does not preclude the route, (iii) the short distance to both the mitral and aortic valve allows a direct control and manipulation of the guidewires and encounters less hinder of severe regurgitant jets in crossing a defect, (iv) simultaneous occluder device implantation is easily performed, (v) coaxial alignment of the catheter and the lesion are relatively easily accomplished, and (vi) procedure times are short. Because of these reasons, we chose to implement only the transapical approach to build up experience.
The various results of transapical transcatheter PVL closure in literature are listed in Table 5 . 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Most transapical procedures are performed transcutaneously, with direct puncture of the left ventricle. This technique is less invasive compared with open access, but is associated with a risk of coronary artery dissection that may be reduced with preprocedural computed tomography. 15, 29 The advantage of open versus transcutaneous transapical access is that it provides a direct visualization of the cardiac apex and enables the use of multiple sheaths for simultaneous occluder device implantation.
We used a single U-stitch to close the apical access site in the first 10 cases. Because of the high rate of apical bleeding (n=3; 30%), we changed our strategy to double pledgeted reinforced purse-string stitches. Thereafter, the rate of apical bleeding reduced significantly (n=1; 4%). Besides surgical closure, it is also possible to secure the left ventricular apex with an occluder device such as the ventricular septal defect occluder as used by Ruiz et al, 9 which seems equally effective.
Device Selection
For transcatheter PVL closure, no dedicated devices are currently available. We mainly use the AVPIII, which is not available in the United States where the AVPII is most commonly used. In contrast to the AVPII, the AVPIII is oval shaped instead of circular. This results in a decreased surface area with a reduced risk of overlapping with the valve area. Furthermore, the retention rims of the AVPIII are relatively small (2 mm), further minimizing the risk of leaflet interference. In longer defects, we try to use multiple plugs rather than another type of device. In broader defects further located from the prosthetic leaflets, a single device with larger discs might be more appropriate. Although previously described as a purpose specific device, 21 the AVPIII is a vascular closure device not designed to seal PVL. This might explain why we experienced some degree of residual PVL. Even with numerous devices, we regularly had to accept a trace to mild residual PVL. Often, residual PVL originated from between the devices, indicating some form of malcoaptation. Improvement due to endothelialization in a later stadium did not occur, possibly due to a high regurgitant flow.
PVL Closure
The overall procedure success in this cohort was 86%. Procedure success was highest in aortic lesions. No other relevant anatomic or procedural factors could be identified. In a review of 100 patients, procedure success was reported 82%. 30 However, procedure success was generously defined as a correct device position without dislodgement or embolization. There are 2 large cohorts described by Ruiz et al 9 and Sorajja et al. 16 Ruiz et al 9 reported a procedure success of 86% in 43 patients, without 30-day mortality (5%) and residual moderate to severe PVL (unknown). Sorajja et al 16 reported a procedure success of 77% in a large cohort of 115 patients, of which 13 were treated via transcutaneous transapical approach. More recently, the same authors reported a procedure success of 90% in 200 patients. 31 The 30-day mortality in our cohort series was 5%. The 1-year survival rate was 63% in our cohort compared with 30% to 88% at 8 to 10 years after reoperation. 32, 33 This difference could be partially explained by the high-risk population treated in our cohort (mean logistic European System for Cardiac Operative Risk Evaluation of 27%). Also, residual PVL is important: we found that moderate to severe residual PVL was associated with all-cause mortality (hazard ratio, 3.9; Figure 4A ).
Mitral PVL
In our cohort, most treated PVLs were in mitral position (81%) and located posterolaterally (56%). Previous associations between PVL and chronic kidney disease or atrial size could not be confirmed. 34 The PVL location was not associated with outcome. Because of the direct nature of the approach, the short distance, and coaxial alignment to the defect, the transapical approach facilitates crossing and advancing sheaths and delivery catheters through the PVL, especially for posteromedially located defects, which are often difficult to access from the trans-septal antegrade approach. The mitral defects in this cohort were relatively large, with a mean circumference of 19%. The procedure time was short: 79 minutes of surgery and 48 minutes of PVL closure. Procedure success was 83%, which is comparable with current literature. 9, 16, 30, 31 
Aortic PVL
In our limited experience with the transfemoral retrograde approach for aortic PVL, we noticed that the crossability was relatively easy, but the pushability of the catheters was impaired compared with the transapical approach. To provide adequate support of the device delivery catheter, the use of an arteriovenous wire loop might be an option. Alternatively, we decided to close all aortic defects in a transapical manner.
Using the transapical approach, the crossability of an aortic PVL is more difficult because the alignment is less straightforward compared with mitral defects. This is especially the case for anterior located aortic defects (9 o'clock; Figure 2 ). Moreover, subaortic septal hypertrophy may further impede the crossability. Procedure success was 100%, although this could have been biased by the low sample size for aortic lesions (n=7).
Functional Outcomes
To our knowledge, this is the first study that analyzed 6-MWT and QoL after transcatheter PVL closure. Overall, the mean distance covered by 6-MWT improved with ≈50 m at 6 months. This is above the range of previously reported thresholds (31-42 m). 35 Furthermore, a distance covered by 6-MWT<300 m has been previously found to predict mortality. 14 In our cohort, a 6-MWT of ≥300 m at baseline was associated with an improved 1-year survival ( Figure 4C) . Moreover, the 6-MWT distance was associated with the QoL, which improved significantly at 6 months.
Efficacy at 3-month and 1-year follow-up was 51% and 31%, respectively. This composite was primarily driven by a persistent NYHA functional class >2. Despite a moderate efficacy, QoL and functional capacity measured with the 6-MWT increased. In our opinion, these factors should be the main goal of intervention in this high-risk population.
Clinical efficacy seemed to be only dependent of baseline parameters and comorbidities. Hemolytic anemia was most prevalent in patients without efficacy and with a trace of PVL at follow-up. This might indicate that a small residual PVL remains symptomatic due to a persistent hemolytic anemia due to a high regurgitant flow.
Assessment of Outcomes
Evidence on transcatheter PVL closure is limited because most publications are single case reports and no uniformity ? indicates unknown due to lack of data; ASD, atrial septal defect; AVP, Amplatzer vascular plug; PDA, patent ductus arteriosus; PVL, paravalvular leakage; and VSD, ventricular septal defect.
*The listed occluder devices concern all the devices used in the complete study, and not all of them may have been use for transapical PVL closure. †Clinical efficacy at 3 mo. ‡Twenty-four of 43 procedures were performed via the transapical transcutaneous approach, results are provided for the entire cohort. §Thirteen of 115 procedures were performed via the transapical transcutaneous approach for which the results are provided. ║New designed device.
in end point definition exists, compromising comparability and interpretability of the study results. To overcome this issue, we emphasize the use of uniformly defined end points in further studies. In our opinion, the VARC-2 10 consortium on end point definition for transcatheter aortic valve implantation procedures provides most suitable success, safety, and efficacy measures for analysis of transcatheter PVL closure. 10
Future
Besides the lack of a uniform definition, variability in clinical success in the current literature might partially be explained by an incomplete closure of the defect in the absence of a specifically designed device. The first use of a specifically designed device has recently been reported. 17 Until devices like these become available, transcatheter PVL closure should be reserved for high-risk patients who had severe symptoms related to significant PVL in whom optimal medical treatment fails and a heart team agrees that medical factors either preclude operation or are high risk for surgical valve replacement.
Study Limitations
The present investigation is a single-center prospective study with consequent inherent limitations. This is reflected by our limited experience with the retrograde or trans-septal approach. Furthermore, the sample size is relatively small, and the follow-up for laboratory tests and the 6-MWT and Minnesota Living with Heart Failure Questionnaire is partially incomplete. Finally, no control group is described to allow comparison with reoperation or optimal medical treatment.
Conclusions
Transcatheter PVL closure using an open transapical approach in high-risk patients has a high procedural success rate with an acceptable risk of adverse outcomes, similar to other reported approaches to closure. This is the first study to prove a moderate efficacy with an increased functional capacity and QoL after transapical PVL closure. Residual PVL is associated with 1-year mortality.
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